Literature DB >> 8913730

Correlation between the ETV6/CBFA2 (TEL/AML1) fusion gene and karyotypic abnormalities in children with B-cell precursor acute lymphoblastic leukemia.

S Fears1, C Vignon, S K Bohlander, S Smith, J D Rowley, G Nucifora.   

Abstract

The recently identified ETV6/CBFA2 (formerly known as TEL/AML1) fusion gene occurs as a result of the t(12;21)(p12;q22). Initial reports have indicated that the fusion transcript occurs in up to 30% of children diagnosed with B-cell precursor (CD10+, CD19+) acute lymphoblastic leukemia (ALL). In order to characterize the incidence of the t(12;21) at both the chromosomal level as well as the RNA transcript level, we have used a combination of classical cytogenetics, reverse transcriptase-polymerase chain reaction (RT-PCR), and fluorescence in situ hybridization (FISH) to examine the bone marrow of 34 children diagnosed with B-cell precursor ALL. Nine of the 34 patient samples expressed the ETV6/CBFA2 transcript. When the results of RT-PCR were compared with the conventional karyotype, the fusion was present in 3 of 10 (33%) with chromosome 12 abnormalities, none of whom had an obvious t(12;21). The transcript was also detected in 5 of the 12 (41%) bone marrow samples with other abnormalities and in 1 of 12 (8%) samples with a normal karyotype. Seven of the 9 RT-PCR positive patient samples were studied with FISH. Of the 7, FISH confirmed the ETV6/CBFA2 fusion in 6. One other patient with a 12p abnormality had evidence for the fusion using FISH which was not detected by RT-PCR. Our results not only confirm that the frequency of the t(12;21) is unusually high in childhood B-cell precursor ALL, but also that none of the translocations in our series was detected with conventional cytogenetic techniques.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8913730     DOI: 10.1002/(SICI)1098-2264(199610)17:2<127::AID-GCC8>3.0.CO;2-7

Source DB:  PubMed          Journal:  Genes Chromosomes Cancer        ISSN: 1045-2257            Impact factor:   5.006


  7 in total

1.  ETV6/RUNX1 induces reactive oxygen species and drives the accumulation of DNA damage in B cells.

Authors:  Hans-Peter Kantner; Wolfgang Warsch; Alessio Delogu; Eva Bauer; Harald Esterbauer; Emilio Casanova; Veronika Sexl; Dagmar Stoiber
Journal:  Neoplasia       Date:  2013-11       Impact factor: 5.715

2.  Functional characterization of ETV6 and ETV6/CBFA2 in the regulation of the MCSFR proximal promoter.

Authors:  S Fears; M Gavin; D E Zhang; C Hetherington; Y Ben-David; J D Rowley; G Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  1997-03-04       Impact factor: 11.205

3.  Posttranslational modification of TEL and TEL/AML1 by SUMO-1 and cell-cycle-dependent assembly into nuclear bodies.

Authors:  S R Chakrabarti; R Sood; S Nandi; G Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  2000-11-21       Impact factor: 11.205

4.  Modulation of TEL transcription activity by interaction with the ubiquitin-conjugating enzyme UBC9.

Authors:  S R Chakrabarti; R Sood; S Ganguly; S Bohlander; Z Shen; G Nucifora
Journal:  Proc Natl Acad Sci U S A       Date:  1999-06-22       Impact factor: 11.205

5.  Cooperation of ETV6/RUNX1 and BCL2 enhances immunoglobulin production and accelerates glomerulonephritis in transgenic mice.

Authors:  Eva Bauer; Michaela Schlederer; Ruth Scheicher; Jaqueline Horvath; Petra Aigner; Ana-Iris Schiefer; Renate Kain; Heinz Regele; Gregor Hoermann; Günter Steiner; Lukas Kenner; Veronika Sexl; Andreas Villunger; Richard Moriggl; Dagmar Stoiber
Journal:  Oncotarget       Date:  2016-03-15

Review 6.  Pathogenesis of ETV6/RUNX1-positive childhood acute lymphoblastic leukemia and mechanisms underlying its relapse.

Authors:  Congcong Sun; Lixian Chang; Xiaofan Zhu
Journal:  Oncotarget       Date:  2017-05-23

7.  Blocking ETV6/RUNX1-induced MDM2 overexpression by Nutlin-3 reactivates p53 signaling in childhood leukemia.

Authors:  U Kaindl; M Morak; C Portsmouth; A Mecklenbräuker; M Kauer; M Zeginigg; A Attarbaschi; O A Haas; R Panzer-Grümayer
Journal:  Leukemia       Date:  2013-11-18       Impact factor: 11.528

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.